Literature DB >> 3491344

Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease.

P L McGeer, H Kamo, R Harrop, E G McGeer, W R Martin, B D Pate, D K Li.   

Abstract

Positron emission tomography (PET) with fluorodeoxyglucose (FDG), magnetic resonance imaging (MRI), and CT were carried out in a patient with Alzheimer's disease 16 months before he died. At autopsy, the gross appearance of the brain correlated with MRI and CT, which showed some regional atrophy. These were much less revealing than PET, which correlated with microscopic findings of neuronal loss and proliferation of glia. In areas of moderately impaired local cerebral metabolic rate of glucose, as revealed by reduced FDG uptake, there was some gliosis, primarily around the numerous senile plaques. In areas of severe metabolic impairment, there was a profound loss of neurons, extensive gliosis, and a diminished appearance of plaques. PET-FDG is a better measure of the severity of Alzheimer's disease than MRI or CT, because it reflects the degree of neuronal pathology.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3491344     DOI: 10.1212/wnl.36.12.1569

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Cognitive reserve modulates functional brain responses during memory tasks: a PET study in healthy young and elderly subjects.

Authors:  Nikolaos Scarmeas; Eric Zarahn; Karen E Anderson; John Hilton; Joseph Flynn; Ronald L Van Heertum; Harold A Sackeim; Yaakov Stern
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

2.  Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography.

Authors:  H Karbe; M Grond; M Huber; K Herholz; J Kessler; W D Heiss
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

3.  Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease.

Authors:  R Mielke; R Schröder; G R Fink; J Kessler; K Herholz; W D Heiss
Journal:  Acta Neuropathol       Date:  1996       Impact factor: 17.088

4.  Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.

Authors:  Val J Lowe; Emily S Lundt; Sabrina M Albertson; Scott A Przybelski; Matthew L Senjem; Joseph E Parisi; Kejal Kantarci; Bradley Boeve; David T Jones; David Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Melissa E Murray
Journal:  Alzheimers Dement       Date:  2019-06-04       Impact factor: 21.566

5.  Single photon emission computed tomography in motor neuron disease with dementia.

Authors:  H Sawada; F Udaka; Y Kishi; N Seriu; T Mezaki; M Kameyama; M Honda; M Tomonobu
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

6.  Biochemical measurements in Alzheimer's disease reveal a necessity for improved neuroimaging techniques to study metabolism.

Authors:  A Najlerahim; D M Bowen
Journal:  Biochem J       Date:  1988-04-01       Impact factor: 3.857

7.  Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance.

Authors:  Nikolaos Scarmeas; Christian G Habeck; Eric Zarahn; Karen E Anderson; Aileen Park; John Hilton; Gregory H Pelton; Matthias H Tabert; Lawrence S Honig; James R Moeller; Davangere P Devanand; Yaakov Stern
Journal:  Neuroimage       Date:  2004-09       Impact factor: 6.556

8.  Quantification of functional deficit in Alzheimer's disease using a computer-assisted mapping program for 99mTc-HMPAO SPECT.

Authors:  H Karbe; A Kertesz; J Davis; B J Kemp; F S Prato; R L Nicholson
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

9.  Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.

Authors:  Ann D Cohen; Julie C Price; Lisa A Weissfeld; Jeffrey James; Bedda L Rosario; Wenzhu Bi; Robert D Nebes; Judith A Saxton; Beth E Snitz; Howard A Aizenstein; David A Wolk; Steven T Dekosky; Chester A Mathis; William E Klunk
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

10.  Piracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport.

Authors:  Richard J Naftalin; Philip Cunningham; Iram Afzal-Ahmed
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.